Cas:1445-19-8 ans-na manufacturer & supplier

Chemical Name:ans-na

CAS.NO:1445-19-8

Synonyms:8-Anilino-1-naphthalenesulfonic Acid Sodium Salt;ANS-Na;sodium,8-anilinonaphthalene-1-sulfonate;EINECS 215-890-8

Molecular Formula:C₁₆H₁₂NNaO₃S

Molecular Weight:321.32600

HS Code:2921499090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.409g/cm3

Index of Refraction:

PSA:77.61000

Exact Mass:321.04400

LogP:4.64130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 8-Anilino-1-naphthalenesulfonic Acid Sodium Salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 215-890-8 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 215-890-8 Use and application,EINECS 215-890-8 technical grade,usp/ep/jp grade.

Related News: A week after the memo was released to employees, Reuters reported that the Justice Department had launched a criminal investigation focused on the Branchburg plant. That same day, May 27, Lilly reported to the U.S. Securities and Exchange Commission that it had received a subpoena from the department seeking documents related to the factory. ans-na manufacturer The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China��s public hospitals, where most Chinese people buy their drugs. ans-na supplier At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. ans-na vendor As far as chemical raw materials are concerned, China occupies a large share in the field of bulk raw materials and has become one of the world’s largest suppliers of chemical raw materials. ans-na factory Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.